论文部分内容阅读
美国国立卫生研究所为其研究人员发现的两千多个 CDNA(互补 DNA)序列申请专利权的行动在国际科学界引起了一场轩然大波。许多国家的科学家谴责该研究所的这一企图,认为在目前阶段向基因片断授予专利权是完全不合适的。最近美国专利局驳回了国立卫生研究所的专利申请,从而使这一争论暂告一段落。观察家们认为,专利局的此项裁决很有可能确立一项新的判例,它将使任何与现在已公布的基因序列有相同片断(哪怕是极小的相同片断)的基因都不可能获得专利。
The action taken by the National Institutes of Health on patenting more than 2,000 sequences of CDNA discovered by its researchers caused an uproar in the international scientific community. Scientists in many countries condemned the Institute's attempt to conclude that it was totally inappropriate to grant patents to genetic fragments at this stage. The controversy came to an end when the U.S. Patent Office recently dismissed the patent application from the National Institutes of Health. Observers believe the patent office's decision is likely to establish a new case that will make it impossible to patent any gene that shares the same (even the same) fragment as the currently published gene sequence .